⌘K
Loading ticker…
As of 2026-08-24, Protalix BioTherapeutics, Inc. Common Stock (PLX) has a 3-month relative strength percentile of 74 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 55. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 5.3%, relative volume 0.53×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
PLX is in a stage 1 base, week 2. Currently in a 128-day base; basing ADR 4.5% (broad 5.3%). VCP detected: inconclusive. RS line below base-start high. Distance from 50d / 200d: 3.7% / 8.4%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
PLX is held by 8 ETFs as of May 2026. Top owner: VTWO at 0.00% weight, $786K notional. Top 3 carry $941K.
Held by 18 ETFs · $7M across latest filings · largest weight 0.04% (IWC).
Top 8 by value, from SEC N-PORT-P filings dated May 2026.
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Related searches
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| 0.00% |
| $6K |
| — |
| HDG | 0.00% | $143 | — |
| RB | 0.00% | $44 | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | PLX Jan avg: 13.65% median: 21.56% win: 75% σ: 22.71% n: 4 2022-04-12 → 2026-07-31 | PLX Feb avg: 13.93% median: 17.75% win: 75% σ: 13.17% n: 4 2022-04-12 → 2026-07-31 | PLX Mar avg: -7.31% median: -7.23% win: 50% σ: 18.93% n: 4 2022-04-12 → 2026-07-31 | PLX Apr avg: 4.83% median: -0.92% win: 40% σ: 20.83% n: 5 2022-04-12 → 2026-07-31 | PLX May avg: -15.07% median: -1.86% win: 20% σ: 22.02% n: 5 2022-04-12 → 2026-07-31 | PLX Jun avg: -0.50% median: -4.31% win: 40% σ: 7.37% n: 5 2022-04-12 → 2026-07-31 | PLX Jul avg: -6.02% median: -2.75% win: 20% σ: 8.52% n: 5 2022-04-12 → 2026-07-31 | PLX Aug avg: 4.11% median: 5.44% win: 75% σ: 12.64% n: 4 2022-04-12 → 2026-07-31 (current) | PLX Sep avg: 8.23% median: 0.92% win: 50% σ: 24.82% n: 4 2022-04-12 → 2026-07-31 | PLX Oct avg: 5.24% median: 3.68% win: 75% σ: 7.15% n: 4 2022-04-12 → 2026-07-31 | PLX Nov avg: 4.83% median: -1.39% win: 50% σ: 30.95% n: 4 2022-04-12 → 2026-07-31 | PLX Dec avg: 13.21% median: 13.59% win: 100% σ: 10.19% n: 4 2022-04-12 → 2026-07-31 |